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Abstract
Previously, it was reported that SEL1L is able to de-
crease the aggressive behavior of human pancreatic
tumor cells both in vitro and in vivo. To gain insights
into the involvement of SEL1L in tumor invasion, we
performed gene expression analysis on the pancreatic
cancer cell line Suit-2 subjected to two complementary
strategies: upregulation and downregulation of SEL1L
expression by stable transfection of the entire cDNA
under an inducible promoter and by RNA-mediated in-
terference. SuperArray and real-time analysis revealed
that SEL1L modulates the expression of the matrix metal-
loproteinase inhibitors TIMP1 (P < .04–.03) and TIMP2
(P < .03–.05), and the PTEN gene (P < .03–.05). Gene ex-
pression modulations correlate with the decrease in
invasive ability (P < .05) and in accumulation of SEL1L-
expressing cells in G1. Taken together, our data indi-
cate that SEL1L alters the expression of mediators
involved in the remodeling of the extracellular matrix by
creating a microenvironment that is unfavorable to
invasive growth and by affecting cell cycle progression
through promotion of G1 accumulation.
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Introduction
Most studies on SEL1L, the human ortholog of the
Caenorhabditis elegans sel-1 gene [1], have focused on its
role in cancer development and have provided significant
in vitro and in vivo evidence to link its increased expression
to a decrease in tumor aggressiveness.
Previously, it was reported that ectopic and inducible
expression of SEL1L reduces the aggressive behavior of
breast cancer cells, possibly involving cell–matrix inter-
actions. Moreover, its downregulation has been significantly
correlated to poorer outcome in cancer patients [2]. A similar
situation was also found in pancreatic cancer, where in-
ducible expression of SEL1L in stably transfected cells
caused both a decrease in clonogenity and anchorage-
independent growth and a delayed tumor growth when in-
oculated in immunodeficient mice [3]. To investigate the involve-
ment of SEL1L in human breast cancer biology, we used
proteomic approach and global expression screening (Affymet-
rix platform) and found that SEL1L ectopic expression changed
the levels of proteins and transcripts that operate in different
signaling pathways and in cytoskeletal reorganization; several
tumor-associated proteins were also modulated [4].
SEL1L activation has been reported in the early stages of
esophageal, prostate, and non–small cell lung cancers [5,6]
(Ferrero et al., unpublished).
The function of SEL1L may be associated with degradation
or trafficking of several proteins, as revealed in yeast, plant,
and nematode studies. In Saccharomyces cerevisiae, the
HRD3 protein is required for the degradation of malfolded
endoplasmic reticulum (ER)–resident proteins [7]. InC. elegans,
sel-1, along with ABU-1, is a component of cell survival path-
way that is induced when unfolded proteins accumulate in
the ER [8]. The SEL1L protein of Arabidopsis thaliana is a
membrane-anchored glycoprotein that increases under ER
stress [9]. It has also been reported that the human SEL1L
gene is induced in response to ER stress and contributes, along
with HRD1, to the protection of cells by degrading unfolded
proteins accumulated in the ER [10]. ER stress has been
implicated in the pathogenesis of a variety of human diseases,
including neural degenerative diseases, diabetes, viral patho-
genesis, and cancer [11].
To understand the role of SEL1L in human pancreatic
cancer, we used the cell line Suit-2 containing the entire SEL1L
cDNA [3] and two complementary technical strategies: cDNA
macroarray (GEArray Q Series Human Tumor Metastasis Gene
Array; DBA, Segrate, Italy) and RNA-mediated interference of
SEL1L de novo transcription.
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Here we demonstrate that SEL1L triggers an antitumor
response by modulating the expression of TIMP1, TIMP2,
and PTEN genes. All these gene products have widely been
studied in several aspects of cancer development and pro-
gression [12,13]. Here we also show that gene expression
modulations observed in SEL1L-expressing cells correlate
with their decreased invasive ability and with alteration of cell
cycle progression.
Materials and Methods
Cell Culture and In Vitro Induction of Exogenous
SEL1L Transcript
The human pancreatic cancer cell line Suit-2 stably trans-
fected with the entire SEL1L-coding region driven by a dexa-
methasone (DEX)– inducible promoter as well as control
mock-transfected cells were grown in RPMI 1640 (Micro-
biological Associates, Walkersville, MD) supplemented with
10% fetal bovine serum (Hyclone, Euroclone, Devon, UK),
penicillin/streptomycin (100 IU/ml), and G418 sulfate antibi-
otic (200 mg/ml) in a humidified chamber (95% air and 5%
CO2) at 37jC. Cells were regularly seeded to maintain ex-
ponential growth.
For experimental purposes, the cells were treated for 7 to
14 days with 1 mM DEX, after which they were harvested and
analyzed by reverse transcription–polymerase chain reaction
(RT-PCR), Northern blot analysis, and Western blot analysis.
Northern Blot Analysis
Total RNA (20 mg) from cultured cells was isolated using
the Total Quick RNA Kit (Talent, Trieste, Italy) and fraction-
ated in denatured agarose gels using well-standardized
procedures. Gel-purified, double-stranded DNA probes were
labeled with [32P]dCTP using a random primer labeling kit
(Promega, Madison, WI). Hybridization was performed over-
night at 42jC. RNA loading was normalized by hybridizing
the stripped blots with 32P-labeled HPRT DNA probe. North-
ern blots were imaged and quantified using the Quanty one
program (Bio-Rad Laboratories S.r.l., Segrate, Italy). The ex-
periments were repeated twice using independent RNA prep-
arations. The oligonucleotide primer sequences used to
amplify the DNA probes are as follows:
RT-PCR Analysis
Total RNA (1 mg) treated with RNase-free DNaseI (Clon-
tech, Palo Alto, CA) was used in each RT reaction containing
5 mM MgCl2, 1 reaction buffer [50 mM Tris–HCl (pH 8.8),
8 mM MgCl2, 30 mM KCl, and 1 mM dithiothreitol], 1 mM
dNTPs, 5 U of RNase inhibitor (RNAsin), 0.8 mg of oligo-
p(dT)15 primer, 1.6 mg of random primer, and 15 U of Avian
Myeloblastosis Virus Reverse Transcriptase (Amersham,
Piscataway, NJ). The reaction mixture was incubated for
10 minutes at 25jC, and for 60 minutes at 42jC. The enzyme
was denatured at 99jC for 5 minutes and chilled on ice. PCR
amplifications were performed with a Perkin-Elmer (Foster
City, CA) thermal cycler using 2 ml of RT product per reaction.
PCR conditions used to specifically detect SEL1L induction
and downmodulation were as follows: 94jC for 3 minutes,
followed by 20 to 26 cycles at 94jC for 1 minute, annealing
at 60jC for 1 minute, extension at 72jC for 1 minute, and a
final extension at 72jC for 5 minutes.
PCR conditions used to detect constitutive HPRT, Activin
receptor II, and TIMP1–TIMP2–MMP1–MMP7–PTEN–
Activin A expressions were as follows: 3 minutes at 94jC,
followed by 23 to 26 cycles at 94jC for 1 minute, annealing
at 55jC to 63jC for 1 minute, extension at 72jC for 1 minute,
followed by a final extension at 72jC of 5 minutes.
All the PCR products were electrophoresed on 1.5% aga-
rose gels and stained with ethidium bromide.
Sets of primers used to amplify HPRT and MMP7
genes are listed above, whereas the SEL1L primer set is
as follows:
cDNA Expression Array
The commercially available SuperArray (GEArray Q Se-
ries Human Tumor Metastasis Gene Array; DBA) was used
to compare the gene expression profiles of the pancre-
atic cancer cell line stably transfected with SEL1L cDNA
and pDEX.1 constructs. The arrays were handled following
the manufacturer’s protocol. Briefly, total RNA (3 mg) from
each cell line was reverse-transcribed into 32P-labeled
cDNA using MMLV reverse transcriptase. Probes were
purified and used to hybridize the filters overnight at
60jC. Blots were then washed twice with 2 SSC/1% SDS
and with 0.1 SSC/0.5% SDS at 60jC. Damp membranes
were wrapped immediately and exposed to X-ray film. The
GEArray Analyzer version 1.2 software was used to interpret
the results. The SuperArray contains 96 functionally well-
characterized genes involved in several tumor metastatic
processes and grouped according to their functions and struc-
tural features into seven categories, including growth factors
and receptors, cell–cell and cell–matrix interactionmolecules,
metastasis-associated proteases, protease inhibitors, signal
transduction molecules, oncogenes, and metastasis suppres-
sors. Controls are represented by four potentially normalized
MMP1 5V-cctccactgctgctgctgct-3V
5V-gggagagtccaagagaatgg-3V (770 bp)
MMP7 5V-gaatgttaaactcccgcgtc-3V
5V-catccgtccagcgttcatc-3V (390 bp)
TIMP1 5V-ccctggcttctggcatcctg-3V
5V-ggacctgtggaagtatccgc-3V (280 bp)
TIMP2 5V-gtagtgatcagggccaaagg-3V
5V-ctggtacctgtggttcaggc-3V (320 bp)
PTEN 5V-cgaactggtgtaatgatatg-3V
5V-catgaacttgtcttcccgtc-3V (330 bp)
HPRT 5V-aattatggacaggactgaacgtc-3V
5V-cgtggggtccttttcaccagcaag-3V (388 bp)
SEL1L 5V-CCTCAGAGTAATGAGACAGCTCTCC-3V
5V-GCCACTGGCATGCATCTGAGC-3V (314 bp)
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features (glyceraldehyde-3-phosphate dehydrogenase, pep-
tidylprolyl isomerase A, ribosomal protein L13a, and b-actin),
plasmid pUC18, and blank. The experiment was performed
more than three times using different preparations of RNA.
Student’s t test was used to determine statistical significance.
Western Blot Analysis
Cells were lysed using a buffer containing 50 mM Tris–
HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 0.5% NP40,
10 mg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride.
Protein concentration was determined by the Bradford assay;
40 mg of each sample was resolved in 10% SDS polyacryl-
amide gel, and Western blot analysis was performed as pre-
viously described [14]. Monoclonal antibody MSEL1 was used
at 10 mg/ml.
siRNA Transfection
Two different chemically synthesized siRNA targeting
SEL1L (NM_005065) (siRNA-SEL1L-1 and siRNA-SEL1L-2)
and one scrambled siRNA (siRNA control) were purchased
from Ambion, Huntingdon, UK (predesigned siRNA-annealed
standard purity). The siRNA were introduced into Suit-2
cells using two different transfection agents (siPORT amine
and siPORT lipid; Ambion), according to the manufacturer’s
instructions. Briefly, the cells were seeded into six-well
plates at a density of 1  105 cells/well. The transfection
agents (3 ml of siPORT lipid and 8 ml of siPORT amine) and the
siRNA complex were added to the cells and incubated for 24,
48, and72hours. The final concentration of siRNAwas60mM.
Each assay was performed in duplicate in at least five inde-
pendent experiments.
Real-Time PCR
Real-time PCR was used to quantify the expression of
target genes in siRNA-Suit-2 cells, using the iCycler iQ real-
time detection system (Bio-Rad) and SYBR Green. Real-
time PCR amplifications were performed using 20 ng of
cDNA, 2 Platinum SYBR Green qPCR SuperMix-UDG
(Invitrogen, S. Giuliano M.se, Italy), 50 Rox Dye, and 100 nM
forward and reverse gene-specific primers. The cycling pro-
gramwas as follows: 5minutes at 95jC, followed by 40 cycles
of 15 seconds at 94jC, 30 seconds at 60jC, and 50 seconds
at 72jC. To assess PCR specificity, melting curves from
55jC to 95jC in 0.5jC steps of 10 seconds each were gener-
ated. A relative standard curve was generated by amplifying
serial dilutions of cDNA obtained from siRNA-control-Suit-2.
The standards and cDNA samples were amplified in tripli-
cate in the same reaction plate in at least three indepen-
dent experiments. The amount of product in each sample
was quantified using the threshold cycle (Ct) method normal-
ized to the ribosomal protein S14 gene. PCR efficiencies of
the reactions were between 85% and 95%. Fold increase or
fold decrease in the expression of the target gene relative
to ribosomal protein S14 in each sample was calculated by
the formula: 2DDCt, where DCt =Ct target geneCt S14 and
DDCt = DCt test sample  DCt control. Student’s t test was
used to determine statistical significance.
The sets of primers used to amplify the target genes are
as follows:
In Vitro Invasion Assay
Cell invasion assay was performed using the Chemicon
International system. The kit contains 24 inserts with a poly-
carbonate membrane (8 mm pore size) coated with a thin
layer of ECMatrix (Chemicon International, Temecula, CA), a
reconstituted basement membrane matrix of proteins derived
from the Engelbreth-Holm-Swarm mouse tumor. Briefly, cells
untreated and treated with 1 mMDEX for 1 week were trypsin-
detached and placed in 300 ml of serum-free medium contain-
ing 5%BSA in the presence or absenceofDEX (1 mM)over the
inner chamber of the insert at a density of 1.25 105, whereas
500 ml of serum-free medium containing 20 ng/ml epidermal
growth factor (chemoattractant) was placed in the outer cham-
ber of the insert. The plates were incubated for 48 hours at
37jC. Noninvading cells that remained on the upper surface
of the insert were removed, whereas invasive cells that mi-
grated to the lower surface of themembrane were stained and
counted under a fluorescence plate reader at 485 nm/535 nm.
Each assay was carried out in triplicate in at least three in-
dependent experiments. Student’s t test was used to deter-
mine statistical significance.
Colony Formation on Soft Agar
Cells untreated and treated with 1 mM DEX for 1 week
were trypsin-detached and seeded in duplicate in six-well
plates at a density of 15  103 cells/well in a semisolid
medium containing 0.3% Bacto-Agar (Difco, Detroit, MI) over
a 0.8% agarose layer containing DEX, where indicated.
Fresh medium was added weekly. Colony formation was
scored after 14 days of growth. Each assay was carried out
in duplicate in at least three independent experiments.
Cell Cycle Analysis
Cells untreated and treated with 1 mM DEX for 1 week
were trypsin-detached, washed with PBS, and incubated for
15 minutes with 0.37% NP40 and 20 mg/ml RNAse A (Sigma,
Ribosomal 5V-ggcagaccgagatgaatcctca-3V
protein S14 5V-caggtccaggggtcttggtcc-3V (123 bp)
SEL1L 5V-ctcgctaacaggaggctcagta-3V
5V-catggcatgtgaattgccag-3V (251 bp)
TIMP1 5V-ccctggcttctggcatcctg-3V
5V-ggacctgtggaagtatccgc-3V(280 bp)
TIMP2 5V-aagcggtcagtgagaagga-3V
5V-tctcaggccctttgaacatc-3V (108 bp)
PTEN 5V-cgacgggaagacaagttcat-3V
5V-aggtttcctctggtcctggt-3V (163 bp)
MMP1 5V-ggtctctgagggtcaagcag-3V
5V-tggtccacctttcatgttca-3V (161 bp)
MMP7 5V-tgctcacttcgatgaggatg-3V
5V-tggggatctccatttccata-3V (159 bp)
Activin A 5V-ggagggcagaaatgaatgaa-3V
5V-ccttggaaatctcgaagtgc-3V (102 bp)
Activin receptor II 5V-acacagcccacttcaaatcc-3V
5V-aggagggtaggccatcttgt-3V (144 bp)
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St. Louis, MO) in 1% sodium citrate (pH 7.4). Samples were
then stained for 15 minutes with 1 mg/ml DAPI and analyzed
on a FACSVantage instrument (Becton Dickinson, Milan,
Italy) using an ultraviolet excitation laser beam.
Results
Identification of Genes Modulated by SEL1L Induction
in Pancreatic Cancer Cells
Previously, it was reported that the inducible expression of
SEL1L in the human pancreatic tumor cell line Suit-2 strongly
inhibited its anchorage independence and delayed tumor
growth in nudemice [3]. Togain insights intomolecularmecha-
nisms underlying tumor regression, we compared the gene
expression profile of induced Suit-2-SEL1L to uninduced par-
ental cells and induced/uninduced vector-transfected clones
(Suit-2-pDEX.1) using filter macroarrays. The SuperArray (GE-
Array Q Series Human Tumor Metastasis Gene Array; DBA)
used in our study consists of 96 functionally well-characterized
genes involved in several tumormetastatic processes, four nor-
malized housekeeping genes, and plasmid sequences. Macro-
array analysis was performed more than three times using
harvested cells that were treated for 7 days with DEX, as pre-
viously reported [3].
Among the seven gene categories comprising the array,
‘‘cell–cell and cell–matrix interactions’’ and ‘‘metastasis
supressors’’ displayed significant modulation. Two MMPs
(MMP1 and MMP7) of a total of 23 proteases associated
with metastasis were significantly downmodulated, whereas
two protease inhibitor genes TIMP1 and TIMP2 out of eight
were upregulated, in addition to the metastasis-suppressor
gene PTEN (Table 1).
To validate macroarray results, Northern blot analysis
was performed using selected gene fragments as probes.
A clear and constant decrease of MMP1 and MMP7 gene
expression and an increase of TIMP1 and TIMP2 transcrip-
tion were observed in induced Suit-2-SEL1L cells, confirming
filter array results (Figure 1). A 3.5–3.1-fold and a 4.2–3.7-
fold decrease in the expression of MMP1 and MMP7, re-
spectively, as well as a 1.6–1.53 and 1.3–1.25-fold increase
in the expression of TIMP1 and TIMP2, respectively (Table 1
and Figure 1), were observed when the Suit-2-SEL1L cells
were treated with DEX for 7 days. A further effect was seen
when the Suit-2-SEL1L cells were treated with DEX (MMP1
and MMP7 gene expression decreased by 2.2–2.0 and
2.7–2.35-fold, respectively, whereas TIMP1 and TIMP2 in-
creased by 1.8–1.63 and 1.7–1.8-fold, respectively) for
14 days (Table 1 and Figure 1).
A clear increase in the tumor-suppressor gene PTEN, a
key element in controlling cell growth and survival, was
observed in induced Suit-2-SEL1L cells with respect to con-
trols (1.85–1.7 to 13–11-fold for 7 and 14 days of DEX
treatment, respectively) (Table 1 and Figure 1).
Table 1 indicates fold changes in gene expression using
the GEArray Analyzer software and the Quanty one program
for Northern expression analysis. These values are signifi-
cant, and the respective P values are reported in Table 1.
RNA-Mediated Interference of SEL1L mRNA in
Suit-2 Cells
To determine if inhibition of SEL1L mRNA would specifi-
cally affect genes encoding for cell–matrix proteins as well as
PTEN, the Suit-2 cells were transiently transfected with two
target-specific SEL1L-siRNA (siRNA-SEL1L-1 and siRNA-
SEL1L-2, designed based on the second exon of SEL1L
cDNA). The specificity of RNAi was assessed by simulta-
neously transfecting the Suit-2 cells with a scrambled siRNA
(siRNA-control). Two transfection agents (siPORT lipid and
siPORTamine;Ambion)wereused, andeach transfectionwas
carried out for more than three times per transfection reagent.
Table 2 shows the fold decrease in SEL1L expression
as evaluated by quantitative RT-PCR (qRT-PCR). SEL1L
transcription was inhibited from 3- to 2.5-fold over control
after 48 hours of siRNA-SEL1L-1 treatment. Gene silenc-
ing was already visible 24 hours after transfection, reached
an optimum after 48 hours, and lasted for at least another
24 hours (data not shown). SEL1L mRNA silencing was
stronger with siRNA-SEL1L-1 than siRNA-SEL1L-2, and no
effects were observed on the ribosomal protein S14 gene,
which was used as an internal control. Comparable results
were obtained with the two transfection agents used.
Table 1. Summary of Differentially Expressed Genes Identified by Macroarray and Northern Blot Analysis in Suit-2-SEL1L versus Suit-2-pDEX.1 Cells.
Gene GenBank ID Function Fold Changes*,y
Macroarray* Northern Blot Analysisy
7 daysz 7 daysz 14 days§
Genes downregulated
MMP1 X05231 Metastasis-associated proteases 2 ± 0.2 (P < .05) 3.5–3.1 2.2–2
MMP7 X07819 Metastasis-associated proteases 1.8 ± 0.1 (P < .05) 4.2–3.7 2.7–2.35
Genes upregulated
TIMP1 NM_003254 Protease inhibitors 2 ± 0.18 (P < .04) 1.6–1.53 1.8–1.63
TIMP2 NM_003255 Protease inhibitors 1.3 ± 0.04 (P < .03) 1.3–1.25 1.7–1.8
PTEN U96180 Metastasis suppressor 3.7 ± 0.4 (P < .03) 1.85–1.7 13–11
*The reported ratio indicates the observed average fold increase or fold decrease of gene expression in the induced Suit-2-SEL1L cells versus the uninduced
parental cells and the induced/uninduced mock control (± SD).
yThe reported ratio indicates the observed two-fold increase or decrease of gene expression in the induced Suit-2-SEL1L cells versus the uninduced parental cells
and the induced/uninduced mock control.
zCells were treated with DEX for 7 days.
§Cells were treated with DEX for 14 days.
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Figure 2A shows RT-PCR experiments. As a consequence
of SEL1L interference, Suit-2 cells underwent significant
morphologic changes in that the cells grew in a disorganized
manner, increased in cell volume, lost cell–cell contact, and
acquired a spindle-type shape with numerous extrusions
(Figure 2B). Cell growth rate, however, was unaffected, con-
firming previous results.
SEL1L Directly Modulates the Transcription of TIMP1,
TIMP2, PTEN, Activin A, and Activin Receptor II
We looked at the modulation of MMP1, MMP7, TIMP1,
TIMP2, and PTEN transcription in the Suit-2 cells treated
with siRNA-SEL1L-1 and siRNA-control by qRT-PCR. Al-
though TIMP1, TIMP2, and PTEN significantly decreased
their expression (2.4- to 2-fold, 2- to 1.5-fold, and 2- to
1.5-fold, respectively) after SEL1L downregulation, the
two MMPs (MMP1 and MMP7) were unaffected. However,
a decrease in Activin A and Activin receptor II expres-
sion was observed (2- to 1.5-fold and 2- to 1.5-fold, respec-
tively). Activin A—but not Activin receptor II—modulation
was in agreement with data previously obtained in response
to SEL1L induction [3,15]. Relative P values are listed
in Table 2.
Effect of Exogenous SEL1L Expression on Pancreatic
Cancer Cell Invasion In Vitro
Because genes associated with the extracellular matrix are
of paramount importance in tumor invasion and metastasis,
Figure 1. Northern blot hybridization of RNA extracted from untreated and DEX-treated (for 7 and 14 days, respectively) Suit-2-SEL1L and Suit-2-pDEX.1 cells
using MMP1, MMP7, TIMP1, TIMP2, and PTEN coding DNA fragments as probes. HPRT expression was used as endogenous control. Histograms show
normalized values of gene expression, as determined by imaging through a Quanty one program, and correspond to the representative blot of two experiments
using independent RNA preparations.
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we examined the effects of SEL1L on genes related to cell–
matrix interactions in pancreatic cancer cell invasion through
the use of an extracellular matrix–coated filter (ECMatrix;
Chemicon International). Both Suit-2-SEL1L and mock cells
were pretreated with DEX for 7 days prior to performing
invasion assays. The SEL1L-expressing cells displayed a
lower potential to penetrate Matrigel-coated filters compared
to the uninduced and induced control cells; only a 27%
decrease in the ability to invade the Matrigel was consistently
observed on SEL1L induction, and this was significant at the
P < .05 level (Figure 3A). RT-PCR analysis and Western blot
analysis were performed on RNA and proteins obtained from
untreated and DEX-treated Suit-2-SEL1L cells to ascertain
the induction of SEL1L and the decrease of MMP7 expres-
sion (Figure 3B).
Effect of Exogenous SEL1L Expression on Anchorage-
Independent Growth of Pancreatic Cancer Cells
We further investigated the anti-invasive effects of
SEL1L on anchorage-independent growth. The ability to
grow on soft agar to detect the capacity of tumor cells to
survive and metastasize in vivo is an acceptable method;
therefore, anchorage-independent growth strongly corre-
lates with tumorigenesis and invasiveness. As previously
described, soft agar cloning efficiency was markedly im-
paired in the induced Suit-2-SEL1L cells compared to un-
induced parental cells and mock control [3]. Furthermore,
the majority of the induced SEL1L-expressing cells failed
to locally penetrate and degrade the surrounding semi-
solid medium, exhibiting a drastically altered cellular mor-
phology (Figure 3C).
Effect of Exogenous SEL1L Expression on Cell Cycle
Distribution in Pancreatic Cancer Cells
The effects of SEL1L on cell cycle distribution were
analyzed using DEX-treated and untreated Suit-2-SEL1L
and mock cells. The SEL1L-expressing cells showed an
Table 2. SEL1L Fold Decrease after siRNA-SEL1L-1 in Suit-2 Cells and a
Summary of Differentially Expressed Genes after SEL1L Depletion.
Gene Fold Changes*
SEL1L 3–2.5 ± 0.25 (P < .02)
TIMP1 2.4–2 ± 0.2 (P < .03)
TIMP2 2–1.5 ± 0.25 (P < .05)
PTEN 2–1.5 ± 025 (P < .05)
Activin A 2–1.5 ± 025 (P < .05)
Activin receptor II 2–1.5 ± 025 (P < .06)
The values correspond to the results obtained using the two transfection
reagents (± SEM).
*The reported ratio indicates the observed fold decrease of gene expression
in the siRNA-SEL1L-1-Suit-2 cells versus the siRNA-control-Suit-2 cells
48 hours posttransfection.
Figure 2. Effects of SEL1L downmodulation on target gene expression (A) and on morphologic changes (B) in Suit-2 cells. (A) RT-PCR performed on RNA
obtained from Suit-2 cells treated for 48 hours with siRNA-control (lane 1), siRNA-SEL1L-1 (lane 2), and siRNA-SEL1L-2 (lane 3). The figure shows the
downmodulation of SEL1L expression and the concomitant decreased expression levels of TIMP1, TIMP2, PTEN, Activin A, and Activin receptor II. M, marker,
100 bp; B, blank. HPRT housekeeping gene is used as endogenous control. (B) The figure shows morphologic changes after treating Suit-2 cells for 48 hours with
siRNA-SEL1L-1.
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increase in G1 phase (44.7%) and a decrease in G2 phase
(13.29%) compared to controls (Figure 3D), whereasS phase
was unaffected.
Discussion
This study provides evidence that SEL1L affects the aggres-
sive ability of the pancreatic cancer cell line Suit-2 by re-
organizing the expression of genes involved in cell–matrix
interactions and by promoting cell cycle accumulation in G1
phase. Although G1 phase accumulation may result from the
enhancement of PTEN transcription, the decreased invasive
ability (as revealed by invasion and clonogenity assays)
may be due to the sudden modulation of TIMP1 and TIMP2
gene expression and subsequent effects on MMPs (MMP1
and MMP7 ). In fact, using two opposing experimental ap-
proaches on the same biologic system (Suit-2)—with the first
consisting of upmodulation of SEL1L expression by stably
transfecting the entire cDNA downstream of an induc-
ible promoter, and the second consisting of the knockdown
of SEL1L expression by RNAi—we demonstrated that
SEL1L upmodulation/downmodulation led to upmodulation/
Figure 3. Effects of exogenous SEL1L expression on cell invasion (A), anchorage-independent clonogenity (C), and cell cycle (D) of Suit-2 cells. (A) The invasion
assay was performed on Suit-2-SEL1L and Suit-2-pDEX.1 cells untreated and DEX-treated for 7 days. Invasion was assessed in Matrigel-coated transwell
chambers, as described in Materials and Methods section. Briefly, cells were pretreated with 1 M DEX for 7 days, or grown uninduced and seeded onto the
Matrigel-coated 8-M pore membrane of the upper compartment of each chamber at a density of 1.25  105 cells/well. As a chemoattractant, we used epidermal
growth factor. The chambers were incubated for 48 hours at 37jC. The filters were then removed and stained. The graph shows the number of cells that migrated
into the lower chamber. Induced Suit-2-SEL1L cells show 27% less invasion than uninduced parental cells or uninduced/induced mock control. The data are the
average values from three separate experiments performed in triplicate. Student’s t test, P < .05; bars, ±SE. (B) RT-PCR performed on RNA obtained from Suit-2-
pDEX.1 and Suit-2-SEL1L cells untreated () and DEX-treated (+) for 7 days. The figure shows the induction of SEL1L expression and the concomitant decreased
expression levels ofMMP7 after DEX treatment. B, blank; M, marker, 100 bp. The HPRT housekeeping gene is used as endogenous control. Western blot analysis
performed on proteins obtained from Suit-2-pDEX.1 and Suit-2-SEL1L cells untreated () and DEX-treated (+) for 7 days. The figure shows the induction of SEL1L
protein after DEX treatment. (C) Anchorage-independent clonogenity in soft agar was performed on Suit-2-SEL1L and Suit-2-pDEX.1 cells untreated and DEX-
treated for 7 days. Cells were pretreated with 1 M DEX for 7 days, or grown uninduced and seeded in 0.6% soft agar in duplicate at a density of 1.5  104 cells/
well. Colonies were scored after 14 days. (A1) Uninduced Suit-2-pDEX.1 (original magnification, 10). (A2) Induced Suit-2-pDEX.1 (original magnification, 10).
(A3) Induced Suit-2-pDEX.1 (original magnification, 20). (B1) Uninduced Suit-2-SEL1L (original magnification, 10). (A2) Induced Suit-2-SEL1L (original
magnification, 10). (A3) Induced Suit-2-SEL1L (original magnification, 20). (D) Cell cycle analysis was performed on Suit-2-SEL1L and Suit-2-pDEX.1 cells
untreated and DEX-treated for 7 days. The graph represents the fold increase or fold decrease of specific cell cycle phases observed in the induced Suit-2-SEL1L
cells versus the uninduced parental and uninduced/induced control mock. Bars, ±SE.
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downmodulation of PTEN, TIMP1, and TIMP2 genes. As for
the pattern of MMPmodulation, contrasting results have been
obtained. Although increasing levels of SEL1LmRNA caused
the downmodulation of MMP1 and MMP7 expression, inter-
fering SEL1L transcription did not affect the levels of these two
genes. This could be explained in two ways: 1) MMP modu-
lation in the first case may be due to a general perturbation
of the cells as a result of prolonged effects of DEX treatment
(7–14 days) or may be attributable to inhibitor effects of TIMP
genes rather than direct SEL1L regulation; and 2) in SEL1L-
RNAi experiments, the entire process is relatively short, thus
preventing the identification of MMP modulations.
MMPs and their inhibitors play key roles in extracellular
remodeling and are known to be involved in development as
well as several pathological conditions; these proteins have
been associated with invasion and metastasis in cancer
[12,16]. MMP activity is tightly regulated both at the tran-
scriptional level and after secretion by virtue of proenzyme
activators and endogenous proteinase inhibitors, including
TIMP1, TIMP2, TIMP3, and TIMP4. Diseases associated
with high levels of MMPs over the TIMPs enhance proteol-
ysis of the extracellular matrix [17,18]. Inhibitory activities of
TIMPs suggest that the net balance between MMPs and
TIMPs is a major determinant of the proteolytic potential of
tumors. This concept has been supported by several studies
showing that overproduction of TIMPs reduces experimental
metastasis [19], whereas low levels of these inhibitors cor-
relate with tumorigenesis [20]. Hence, their modulations in
the biologic systems under analysis may explain the invasion
assay results presented in this paper.
It is also worth mentioning that the array panel used
contained 12 MMP and 3 TIMP genes, but only two of the
MMPs and TIMPs were actually modulated, indicating the
cell-specific action of the protease family of proteins. This
is in line with previous reports indicating that the increased
expression of MMP7 and the reduced expression of TIMP2
are responsible for the aggressive phenotype of pancre-
atic carcinoma [21,22].
It is still unclear how SEL1L modulates PTEN and extra-
cellular matrix–related genes, but it has been reported that
both MMP1 and TIMP1 are Smad gene targets [23,24] and
that SEL1L induces the expression of both Activin A and
Smad4, which are members of the tumor growth factor (TGF)
b pathway [3,15]. The MMP1 proximal promoter contains a
TGF-b–inhibitory element as well as an AP1 site—two ele-
ments that are essential for Smad interaction; the Smad-
responsive region is contained in the TIMP1 promoter. It can
be hypothesized that SEL1L may elicit its effects through
transcriptional regulation mediated by TGF-b signaling. In
this report, we confirm, through the use of siRNA transfec-
tion, that SEL1L regulates the expression of Activin A gene.
The expression of Activin receptor II was also downmodu-
lated in response to SEL1L depletion, which was in contrast
with our previous results but may be explained by consider-
ing the different points at which expression analysis was per-
formed on the two model systems; thus, the modulation may
be attributable to an earlier response, rather than a later
response. In addition, as a consequence of SEL1L interfer-
ence, Suit-2 cells underwent drastic morphologic changes in
that cells grew in a disorganized fashion, showed an increase
in cell volume and a significant loss of cell–cell contact, and
acquired a spindle-type cell morphology with the presence
of numerous extrusions. Cell growth rate was unaffected, con-
firming our previous results [3].
PTEN RNA levels show a remarkable increase after
several days of ectopic SEL1L induction and cell cycle arrest
in G1 phase. PTEN is a phosphoinositide (PI) 3 phosphatase
that can inhibit cellular proliferation survival, growth, and
motility by inactivating PI3-kinase–dependent signaling
[25,26]. It promotes cell cycle arrest in G1 phase by limiting
the activity of PI3-K/Akt effector [27]. Therefore, SEL1L may
elicit its effects on cell cycle through the upmodulation of
PTEN and Smad4. Because high levels of PTEN mRNA
were observed after 14 days of DEX treatment, it may thus
reflect the generic perturbation of several pathways. It has
been reported that the human and plant SEL1L gene be-
longs to the so-called unfolded protein response genes,
which are induced in response to the accumulation of un-
folded and misfolded proteins in the ER (ER stress) [9,10].
During ER stress, PI3-K/Akt signaling is acutely activated
and governs cell survival by directly counteracting ER stress–
induced cells [28]. The UPR is activated in solid tumors by
hypoxia. Based on this information and on the present results,
which indicate SEL1L’s ability to modulate PTEN expression,
we then hypothesize that SEL1L may attenuate ER stress and
elicit its antitumor response by affecting the PI3-K/Akt signals.
Besides the known activity of PTEN to control cell proliferation,
it was proven to efficiently inhibit invasiveness [29,30]. Although
PTEN upregulation was moderate (but still within the range
of the increase of TIMP1 and TIMP2 transcripts) after DEX
treatment of Suit-2-SEL1 cells for 7 days, it might still contrib-
ute to reverting the invasive phenotype of this cell line. Inter-
estingly, TIMP1 proved to inhibit endothelial cell migration and
to promote PTEN upregulation [31].
Presently, we do not have proteomic data on our ex-
perimental system (Suit-2 cells). Most likely, these proteins
are present in the cells at a certain level; thus, it remains to
be determined whether or not they will change levels on
SEL1L induction.
Presently, we do not know the precise stage during which
SEL1L exerts its anti-invasive activity. Metastasis requires
the interaction of malignant cells with three distinct micro-
environments: the primary organ, the circulation, and the
target organ where a metastatic lesion may develop. Cancer
cell invasion requires several steps: 1) invasion, which in-
cludes loss of cell–cell adhesion, detachment from tumor
mass, and degradation of basement membranes, which en-
ables neoplastic cells to migrate; 2) intravasation, wherein
tumor cells penetrate through the endothelium of the blood or
lymphatic vessels to enter the systemic circulation; and 3)
extravasation, wherein the small number of cells that survive
the voyage through the circulatory system extravasates
through the capillary endothelium at the target organ pa-
renchyma, where they proceed to proliferate in the new sup-
portive microenvironment as micrometastases. Any agent
that can inhibit the early steps of the invasive process may
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be a powerful tool in the prevention of metastasis [32]. It
would then be extremely interesting to dissect the specific
stage during which SEL1L interferences with cancer progres-
sion; however, the lack of model systems that allow the
investigation of the sequential stage of carcinogenesis ren-
ders this analysis very difficult.
By modulating genes related to cell–matrix interactions,
it can be hypothesized that SEL1L may be involved in the
early steps of the metastatic process because MMPs appear
to be important in the early stage of cancer progression (local
invasion and micrometastasis) and may no longer be re-
quired once metastases have been established [33].
Adenocarcinoma of the pancreas is an invasive neoplasm
that is usually lethal. The dismal prognosis of pancreatic
carcinoma is due to: 1) late-stage diagnosis; 2) its high in-
vasive and metastatic potential; and 3) intense desmoplastic
stromal reaction, resulting in low rates of curative resections
and high frequencies of relapse [13,34,35]. Molecular and
cellular processes underlying epithelial–stromal interactions
are of great importance to understanding the biology of the
disease and to developing effective strategies for diagnosis
and treatment. Disturbing the balance between MMPs and
their natural tissue inhibitors is an important target for pan-
creatic tumor therapy as well as for other cancers. Future
direction should focus on a new conceptual basis for the
design of strategies that use SEL1L as a molecule against
these enzymes, thus preventing matrix breakdown.
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